New York, June 13, 2024 - PRISM MarketView - Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX), a specialty pharmaceutical company focused on rare and orphan diseases, announced a research agreement with The School of Pharmacy at University College Cork (UCC) in Ireland. This collaboration, aimed at developing innovative topical formulations of rapamycin (sirolimus), marks a strategic step towards potentially expanding the company’s treatment pipeline for a variety of rare and orphan diseases that currently lack approved therapies.
The partnership will utilize UCC’s advanced dissolvable microneedles technology and other novel formulation approaches to enhance the local delivery of rapamycin, improving its therapeutic effectiveness while offering a painless and minimally invasive delivery method that minimizes infection risk and simplifies disposal.
Under the terms of the agreement, Quoin will fund a research program at UCC to develop several topical rapamycin formulations. Should the research prove successful, Quoin will have the option to continue development and potentially move these formulations into clinical trials. This agreement does not involve any upfront licensing fees, milestone payments, or royalties on future product sales.
“The School of Pharmacy at UCC has a very strong track record in the design of dermal drug delivery technologies, with a particular focus on dissolvable microneedles. We are very pleased and excited to announce the signing of this research agreement, and we believe this partnership with UCC could ultimately lead to the development of proprietary topical rapamycin formulations, which Quoin would have the option to assess clinically as potential treatments for a number of rare and orphan diseases.”
Dr. Michael Myers, CEO of Quoin
Rapamycin is an immunosuppressive drug that inhibits the mTOR signaling pathway and has potential for treating various rare diseases. Its delivery has been challenging due to its molecular size and poor solubility. UCC’s microneedle technology, which uses biodegradable materials that dissolve upon skin contact to release the drug directly into the dermal layers, aims to address these challenges, offering a method that enhances patient comfort and reduces skin trauma, particularly important in treatments for skin-related rare diseases.
About Quoin Pharmaceuticals Ltd.
Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others.
About PRISM MarketView:
Established in 2020, PRISM MarketView is dedicated to the monitoring and analysis of small cap stocks in burgeoning sectors. We deliver up-to-the-minute financial market news, provide comprehensive investor tools and foster a dynamic investor community. Central to our offerings are proprietary indexes that observe emerging sectors, including biotech, clean energy, next-generation tech, medical devices and beyond. Visit us at prismmarketview.com and follow us on Twitter.
Disclaimer:
PRISM MarketView is not a registered or licensed broker-dealer or investment adviser and does not offer investment advice. The information provided in this communication is not intended to constitute an offer to sell, a solicitation of an offer to buy, or a recommendation for any security.
Contact:
Prism MarketView | Stock Market News & Investment Opportunities